CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Aideen Ryan; EVA ERZSEBET SZEGEZDI

doi:10.1016/j.clml.2022.07.011

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

1 Citation (Scopus)

Abstract

The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10⁻⁵ from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.

Original language	English (Ireland)
Pages (from-to)	847-852
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2022.07.011
Publication status	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Daratumumab
Minimal residual disease
Myeloma
Transplant
immunotherapy

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Swan, D. and Henderson, R. and McEllistrim, C. and Naicker, S.D. and Quinn, J. and Cahill, M.R. and Mykytiv, V. and Lenihan, E. and Mulvaney, E. and Nolan, M. and Parker, I. and Natoni, A. and Lynch, K. and Ryan, A.E. and Szegezdi, E. and Krawczyk, J. and Murphy, P. and O'Dwyer, M.
D. Swan and R. Henderson and C. McEllistrim and S.D. Naicker and J. Quinn and M.R. Cahill and V. Mykytiv and E. Lenihan and E. Mulvaney and M. Nolan and I. Parker and A. Natoni and K. Lynch and A.E. Ryan and E. Szegezdi and J. Krawczyk and P. Murphy and M. O\textquotesingleDwyer

Access to Document

10.1016/j.clml.2022.07.011

Cite this

@article{a2ad245314a9402f9050e130f9e960f2,

title = "CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment",

abstract = "The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50\% after transplant and 62.5\% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8\%. Progression-free survival rate at end of maintenance was 81.3\% and estimated 2-year overall survival was 88.9\%. 37.5\% of patients demonstrated sustained MRD negativity to a level of 10−5 from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.",

keywords = "Daratumumab, Minimal residual disease, Myeloma, Transplant, immunotherapy",

author = "Aideen Ryan and SZEGEZDI, \{EVA ERZSEBET\}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = nov,

doi = "10.1016/j.clml.2022.07.011",

language = "English (Ireland)",

volume = "22",

pages = "847--852",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

number = "11",

}

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. / Ryan, Aideen ; SZEGEZDI, EVA ERZSEBET.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, No. 11, 11.2022, p. 847-852.

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

TY - JOUR

T1 - CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma

T2 - Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

AU - Ryan, Aideen

AU - SZEGEZDI, EVA ERZSEBET

PY - 2022/11

Y1 - 2022/11

N2 - The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10−5 from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.

AB - The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10−5 from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.

KW - Daratumumab

KW - Minimal residual disease

KW - Myeloma

KW - Transplant

KW - immunotherapy

UR - https://www.scopus.com/pages/publications/85136081431

U2 - 10.1016/j.clml.2022.07.011

DO - 10.1016/j.clml.2022.07.011

M3 - Article

VL - 22

SP - 847

EP - 852

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Abstract

UN SDGs

Keywords

Authors (Note for portal: view the doc link for the full list of authors)

Access to Document

Other files and links

Fingerprint

Cite this